Working Group Talk "Decoding Lipoprotein(a): From Atherosclerosis to Clinical Implications"
Live Online Event of the ESC Working Group on Coronary Pathophysiology and Microcirculation and on Atherosclerosis & Vascular Biology
Watch On Demand
This focused session delves into the latest insights on Lipoprotein(a) and its role in cardiovascular disease. Designed for cardiologists, researchers, and healthcare professionals, this Working Group Talk will explore how Lipoprotein(a) contributes to atherosclerosis and coronary artery disease.
Hear from experts who discuss the scientific and practical aspects of Lipoprotein(a), covering advanced laboratory testing, current challenges, and actionable strategies for clinical integration, ensuring that participants leave with clear insights and tools to enhance patient care.
This session promises an engaging mix of scientific presentations, real-world applications, patient perspectives, and interactive discussions to help you stay at the forefront of cardiovascular risk management. Don't miss this opportunity to enhance your understanding and application of cutting-edge cardiovascular research in clinical practice.
Learning objectives
- Understand the mechanisms by which Lipoprotein(a) contributes to atherosclerosis, coronary artery disease and cardiovascular risk.
- Laboratory Testing & Challenges: Learn about current laboratory protocols, key biomarkers, and the practical hurdles in standardizing Lipoprotein(a) testing.
- Translate Knowledge into Practice: Explore strategies for integrating Lipoprotein(a) testing into clinical workflows and discuss management approaches informed by the latest research and patient perspectives.
- Patient Perspectives: Gain insights into the patient experience and expectations regarding Lipoprotein(a) testing and management.
Programme
| Presentation | Speaker |
|---|---|
| Lp(a)-associated cardiovascular risk & high-risk populations | Edina Cenko (Bologna, Italy) |
|
Lp(a) in atherosclerosis |
Simon Kraler (Zurich, Switzerland) |
| Demystifying Lp(a) testing: bridging the lab bench and the clinic | Sanja Stankovic (Belgrade, Serbia) |
| Management strategies and emerging therapies | Giuseppe Danilo Norata (Milan, Italy) |
| Patient Perspective | Julie Harris (Manchester, UK) - ESC Patient Forum representative |
| Q&A and interactive discussion | |
Professor Elena Osto
Chair
Doctor Teresa Padro
Chair
Doctor Edina Cenko
Lp(a)-associated cardiovascular risk & high-risk populations
Doctor Simon Kraler
Lp(a) in atherosclerosis
Assistant Professor Sanja Stankovic
Demystifying Lp(a) testing: bridging the lab bench and the clinic
Professor Giuseppe Danilo Norata
Management strategies and emerging therapies